全文获取类型
收费全文 | 12644篇 |
免费 | 905篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 114篇 |
儿科学 | 506篇 |
妇产科学 | 255篇 |
基础医学 | 1605篇 |
口腔科学 | 147篇 |
临床医学 | 1381篇 |
内科学 | 2484篇 |
皮肤病学 | 199篇 |
神经病学 | 1180篇 |
特种医学 | 382篇 |
外国民族医学 | 2篇 |
外科学 | 1727篇 |
综合类 | 181篇 |
一般理论 | 11篇 |
预防医学 | 1067篇 |
眼科学 | 524篇 |
药学 | 1019篇 |
中国医学 | 24篇 |
肿瘤学 | 775篇 |
出版年
2023年 | 59篇 |
2022年 | 113篇 |
2021年 | 294篇 |
2020年 | 169篇 |
2019年 | 251篇 |
2018年 | 310篇 |
2017年 | 262篇 |
2016年 | 261篇 |
2015年 | 332篇 |
2014年 | 411篇 |
2013年 | 620篇 |
2012年 | 977篇 |
2011年 | 978篇 |
2010年 | 528篇 |
2009年 | 450篇 |
2008年 | 756篇 |
2007年 | 851篇 |
2006年 | 786篇 |
2005年 | 799篇 |
2004年 | 719篇 |
2003年 | 675篇 |
2002年 | 610篇 |
2001年 | 158篇 |
2000年 | 150篇 |
1999年 | 145篇 |
1998年 | 160篇 |
1997年 | 122篇 |
1996年 | 85篇 |
1995年 | 95篇 |
1994年 | 107篇 |
1993年 | 76篇 |
1992年 | 108篇 |
1991年 | 95篇 |
1990年 | 73篇 |
1989年 | 83篇 |
1988年 | 74篇 |
1987年 | 46篇 |
1986年 | 59篇 |
1985年 | 61篇 |
1984年 | 55篇 |
1983年 | 53篇 |
1982年 | 69篇 |
1981年 | 58篇 |
1980年 | 46篇 |
1979年 | 55篇 |
1978年 | 44篇 |
1977年 | 33篇 |
1976年 | 25篇 |
1973年 | 29篇 |
1972年 | 29篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
141.
Thierry Andre Philippe Colin Christophe Louvet Erik Gamelin Olivier Bouche Emmanuel Achille Nicolas Colbert Catherine Boaziz Pascal Piedbois Nicole Tubiana-Mathieu Arnaud Boutan-Laroze Michel Flesch Marc Buyse Aimery de Gramont 《Journal of clinical oncology》2003,21(15):2896-2903
PURPOSE: This randomized, 2 x 2 factorial study compared a semimonthly (LVFU2) with a monthly (FULV) regimen of fluorouracil and leucovorin and 24 versus 36 weeks of each regimen as adjuvant treatment of patients with stage II (Dukes' B2) and III (Dukes' C) colon cancer. PATIENTS AND METHODS: LVFU2 was administered semi-monthly for 2 consecutive days as dl- or l-leucovorin (200 or 100 mg/m2, respectively) as a 2-hour infusion, followed by a 400 mg/m2 FU bolus and 600 mg/m2 of FU as a 22-hour continuous infusion. FULV was administered monthly for 5 consecutive days as a 15-minute infusion of dl- or l-leucovorin, followed by 400 mg/m2 of FU as a 15-minute infusion. RESULTS: A total of 905 patients were randomly assigned. The median follow-up was 41 months. Disease-free survival was similar between the LVFU2 and FULV groups (127 v 124 events; hazard ratio [HR] = 1.04; P =.74) and between 24 and 36 weeks of therapy (128 v 123 events; HR = 0.94; P =.63). Analysis of overall survival showed a slight excess in the number of deaths in LVFU2 compared with FULV (73 v 59), but this difference was not statistically significant (HR = 1.26; 95% confidence interval, 0.90 to 1.78; P =.18). The most commonly observed grade 3 to 4 toxicities were neutropenia, diarrhea, and mucositis. Toxicities were significantly lower in the LVFU2 group (all toxicities, P <.001). CONCLUSION: Our data confirm that LVFU2 is less toxic than FULV. At a median follow-up of 41 months, no statistically significant difference could be detected in disease-free or overall survival between the treatment groups or treatment durations. 相似文献
142.
Kelly W Wilhelms Sara A Cutler John A Proudman Lloyd L Anderson Colin G Scanes 《Toxicological sciences》2005,86(1):152-160
The herbicide atrazine is a putative endocrine disruptor. The present studies investigated the effects of atrazine in male Japanese quail during sexual maturation. Atrazine was administered for two weeks in the diet or systemically to birds under long photoperiods. Atrazine had no effect on mortality but depressed both feed intake and growth (average daily gain [ADG] in g/day) at dietary concentrations of 1000 ppm. Atrazine in the diet at 10 ppm, but at no other concentrations, increased testes weight and gonadal-somatic-index and decreased the seminiferous tubule diameter-to-testis weight ratio. However, there were no effects on absolute tubule diameter, relative stage of testicular development, or the presence of a lumen. Atrazine in the diet at 1000 ppm increased circulating concentrations of testosterone but this effect was not observed consistently in all studies. Dietary atrazine at 10 ppm increased circulating concentrations of estradiol. Moreover, in one study, atrazine at 1000 ppm in the diet decreased circulating concentrations of luteinizing hormone. Atrazine administered systemically exerted no effect on indices of growth or reproduction. Atrazine did not mimic the effects of either estradiol or tamoxifen in male quail; thus, atrazine did not exhibit overt estrogenic or anti-estrogenic activity. Conversely, atrazine augmented the effects of testosterone and estradiol on testis regression, presumably by increasing the negative-feedback effects of these sex-steroids on follicle stimulating hormone secretion. It is concluded that atrazine up to 1000 ppm in the diet may exert some effects on reproductive development in sexually maturing male birds, but these are inconsistent and modest. 相似文献
143.
Gary P Zaloga Rafat Siddiqui Colin Terry Paul E Marik 《Nutrition in clinical practice》2004,19(3):201-215
Arginine is a conditionally essential amino acid that plays pivotal roles in maintaining body homeostasis. Arginine is a substrate for protein synthesis but can also be metabolized to various bioactive compounds that include nitric oxide, ornithine, polyamines, creatine phosphate, agmatine, and dimethylarginines. Arginine produces physiologic effects via nitric oxide dependent and independent pathways. Nitric oxide is important for the modulation of vascular tone, inflammation, immune function, endothelial function, platelet and leukocyte adherence, and neurotransmission. Nitric oxide modulates many biochemical processes important for the response to sepsis. Arginine, independent of nitric oxide, is important for growth, wound healing, cardiovascular function, immune function, inflammatory responses, energy metabolism, urea cycle function, and other metabolic processes. Arginine supplementation improves outcomes in animals with sepsis, wounds, ischemia-reperfusion injury, and following thermal injury. Enteral administration of arginine improves endothelial function but has little effect upon hemodynamics during human sepsis. An analysis of clinical studies using enteral formulas with supplemental arginine suggests benefits upon outcome, with no evidence of significant detrimental effects. 相似文献
144.
Under the Weather: Coping with Alcohol Abuse and Alcoholism.By John G. Cooney. Newleaf, Dublin, 2002, 176 pp., £9.99.ISBN 0-7171-3424-5. This is a new edition of a book first published in 1991. Ifthat means the original sold well enough to persuade the publishersthat it was worth updating, one 相似文献
145.
146.
147.
Min Zhang Xing Xie Andy H Lee Colin W Binns C D'Arcy J Holman 《Cancer epidemiology, biomarkers & prevention》2005,14(5):1307-1310
Evidence for an association between indicators of adiposity and survival after ovarian cancer has been inconsistent. A prospective cohort study was conducted in China to examine the relationship between ovarian cancer survival and body mass index (BMI). From the 214 patients recruited in 1999 to 2000 with histopathologically confirmed invasive epithelial ovarian cancer, 207 patients or their close relatives (96.7% of cases) were traced and followed to 2003. Deaths were recorded and Cox proportional hazards regression was used to obtain hazard ratios (HR) and 95% confidence intervals (95% CI) from multivariate models. Reduced survival was observed among patients with BMI > or = 25 kg/m(2) at 5 years before diagnosis (P = 0.001). There were 98 (59.8%) of 164 patients with BMI <25 kg/m(2) survived to the time of interview compared with only 15 women (34.9%) among the 43 patients whose BMI was > or =25 kg/m(2). The HRs significantly increased with higher BMI at 5 years before diagnosis but not at diagnosis nor at age 21 years. The adjusted HR was 2.33 (95% CI, 1.12-4.87) for BMI of > or =25 versus <20 kg/m(2), with a significant dose-response relationship. The HR was 3.31 (95% CI, 1.26-8.73) among patients who had been overweight or obese at age 21 years, but a linear dose-response was not found. We conclude that premorbid BMI may have independent prognostic significance in ovarian cancer. 相似文献
148.
Emma J Chapman Patricia Harnden Philip Chambers Colin Johnston Margaret A Knowles 《Clinical cancer research》2005,11(16):5740-5747
PURPOSE: There are significant differences in reported frequencies, modes of inactivation, and clinical significance of CDKN2A in urothelial cell carcinoma (UCC). We aimed to address these issues by investigating all possible modes of inactivation and clinicopathologic variables in a single tumor panel. EXPERIMENTAL DESIGN: Fifty microdissected UCCs were examined. CDKN2A gene dosage (quantitative real-time PCR), allelic status (microsatellite analysis), hypermethylation (methylation-specific PCR), mutation status (denaturing high-performance liquid chromatography and sequencing), protein expression (immunohistochemistry), and clinicopathologic variables (stage, grade, and disease recurrence during follow-up) were assessed. RESULTS: Exon 2 was underrepresented in 20 of 46 (43%) and exon 1beta in 21 of 46 (46%) of cases. Underrepresentation of exon 2 was accompanied by loss of heterozygosity (LOH) of 9p in 6 of 18 (30%) and of exon 1beta in 11 of 19 assessable cases (58%). Overall, LOH of 9p was identified in 15/41 (37%). Homozygous deletion of exons 2 and 1beta was detected in 16 of 46 (35%) and 10 of 46 tumors (22%), respectively. Co-deletion was most common, but exon 2-specific homozygous deletion was also detected. In tumors without homozygous deletion, p16 promoter hypermethylation was detected in 1 of 18 (6%). Hypermethylation of the p14ARF promoter or mutations in CDKN2A were not observed. Homozygous deletion of exon 2 or LOH on 9p were associated with invasion. Homozygous deletion of exon 2 or exon 1beta was associated with recurrent disease. CONCLUSIONS: These results confirm CDKN2A as a clinically relevant target for inactivation in UCC and show that the true frequency of alteration is only revealed by comprehensive analysis. Our results suggest that CDKN2A may be haploinsufficient in human cancer. 相似文献
149.
150.